

# Sangjune Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8642200/publications.pdf>

Version: 2024-02-01

27  
papers

2,663  
citations

516561

16  
h-index

526166

27  
g-index

29  
all docs

29  
docs citations

29  
times ranked

4418  
citing authors

#	ARTICLE	IF	CITATIONS
1	Transneuronal Propagation of Pathologic $\alpha$ -Synuclein from the Gut to the Brain Models Parkinson's Disease. <i>Neuron</i> , 2019, 103, 627-641.e7.	3.8	830
2	Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. <i>Nature Medicine</i> , 2018, 24, 931-938.	15.2	712
3	Graphene quantum dots prevent $\alpha$ -synucleinopathy in Parkinson's disease. <i>Nature Nanotechnology</i> , 2018, 13, 812-818.	15.6	339
4	$\alpha$ -Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. <i>Molecular Neurodegeneration</i> , 2018, 13, 1.	4.4	143
5	GBA1 deficiency negatively affects physiological $\alpha$ -synuclein tetramers and related multimers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 798-803.	3.3	139
6	Mutant glucocerebrosidase impairs $\alpha$ -synuclein degradation by blockade of chaperone-mediated autophagy. <i>Science Advances</i> , 2022, 8, eabm6393.	4.7	63
7	The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model. <i>Human Molecular Genetics</i> , 2018, 27, 2344-2356.	1.4	55
8	Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson's disease. <i>Brain</i> , 2019, 142, 2380-2401.	3.7	46
9	Macro Histone H2A1.2 (MacroH2A1) Protein Suppresses Mitotic Kinase VRK1 during Interphase. <i>Journal of Biological Chemistry</i> , 2012, 287, 5278-5289.	1.6	42
10	Therapeutic Approaches for Inhibition of Protein Aggregation in Huntington's Disease. <i>Experimental Neurobiology</i> , 2014, 23, 36-44.	0.7	38
11	Vaccinia-Related Kinase 2 Controls the Stability of the Eukaryotic Chaperonin TRiC/CCT by Inhibiting the Deubiquitinating Enzyme USP25. <i>Molecular and Cellular Biology</i> , 2015, 35, 1754-1762.	1.1	31
12	TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson's disease. <i>Neuron</i> , 2021, 109, 3758-3774.e11.	3.8	26
13	Brazilin Isolated from <i>Caesalpinia sappan</i> Suppresses Nuclear Envelope Reassembly by Inhibiting Barrier-to-Autointegration Factor Phosphorylation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 352, 175-184.	1.3	24
14	Vaccinia-Related Kinase 2 Mediates Accumulation of Polyglutamine Aggregates via Negative Regulation of the Chaperonin TRiC. <i>Molecular and Cellular Biology</i> , 2014, 34, 643-652.	1.1	23
15	Modulation of exosome-mediated mRNA turnover by interaction of GTP-binding protein 1 (GTPBP1) with its target mRNAs. <i>FASEB Journal</i> , 2011, 25, 2757-2769.	0.2	22
16	Complement and Coagulation Cascades are Potentially Involved in Dopaminergic Neurodegeneration in $\alpha$ -Synuclein-Based Mouse Models of Parkinson's Disease. <i>Journal of Proteome Research</i> , 2021, 20, 3428-3443.	1.8	21
17	Stress-induced nuclear translocation of CDK5 suppresses neuronal death by downregulating ERK activation via VRK3 phosphorylation. <i>Scientific Reports</i> , 2016, 6, 28634.	1.6	16
18	Preparation and evaluation of BBB-permeable trehalose derivatives as potential therapeutic agents for Huntington's disease. <i>MedChemComm</i> , 2013, 4, 310-316.	3.5	15

#	ARTICLE	IF	CITATIONS
19	Protein kinase C $\delta$ regulates vaccinia-related kinase 1 in DNA damage-induced apoptosis. <i>Molecular Biology of the Cell</i> , 2011, 22, 1398-1408.	0.9	13
20	Glycogen synthase kinase 3 $\beta$ suppresses polyglutamine aggregation by inhibiting Vaccinia-related kinase 2 activity. <i>Scientific Reports</i> , 2016, 6, 29097.	1.6	13
21	Lysosomal Enzyme Glucocerebrosidase Protects against A $\beta$ <sup>1-42</sup> Oligomer-Induced Neurotoxicity. <i>PLoS ONE</i> , 2015, 10, e0143854.	1.1	12
22	Vaccinia-related kinase 2 plays a critical role in microglia-mediated synapse elimination during neurodevelopment. <i>Glia</i> , 2019, 67, 1667-1679.	2.5	12
23	A Novel, Selective c-Abl Inhibitor, Compound 5, Prevents Neurodegeneration in Parkinson's Disease. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 15091-15110.	2.9	9
24	Vaccinia-related kinase 2 modulates role of dysbindin by regulating protein stability. <i>Journal of Neurochemistry</i> , 2018, 147, 609-625.	2.1	6
25	Dopamine D1 Receptor (D1R) Expression Is Controlled by a Transcriptional Repressor Complex Containing DISC1. <i>Molecular Neurobiology</i> , 2019, 56, 6725-6735.	1.9	4
26	HNRNP Q suppresses polyglutamine huntingtin aggregation by post-transcriptional regulation of vaccinia-related kinase 2. <i>Journal of Neurochemistry</i> , 2019, 149, 413-426.	2.1	4
27	Cell-Based Screen Using Amyloid Mimic $\beta$ <sup>23</sup> Expression Identifies Peucedanocoumarin III as a Novel Inhibitor of $\alpha$ -Synuclein and Huntingtin Aggregates. <i>Molecules and Cells</i> , 2019, 42, 480-494.	1.0	3